SEC Form 4 · accession 0001209191-17-067087
Juno Therapeutics, Inc. · JUNO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steve Harr
Officer — CFO & Head, Corp. Development
Period of report
Dec 21, 2017
Accepted (ET)
Dec 22, 2017 · 4:59 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001594864
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 21, 2017 | M | 8,750 | $8.72 | A | 772,082 | D | |
| Common StockF1,F2 | Dec 21, 2017 | S | 8,250 | $44.7373 | D | 763,832 | D | |
| Common StockF1,F3 | Dec 21, 2017 | S | 500 | $45.182 | D | 763,332 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $8.72 | Dec 21, 2017 | M | 8,750 | D | — | Nov 13, 2024 | Common Stock | 8,750 | 98,750 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2014, as amended March 24, 2015.
- F2This transaction was executed in multiple trades at prices ranging from $44.15 to $45.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $45.15 to $45.21. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F41/48th of the shares subject to the option vested and became exercisable on December 14, 2014 and 1/48th of the shares subject to the option shall vest monthly thereafter.